Treace Medical Concepts (TMCI) Net Income towards Common Stockholders (2020 - 2026)

Treace Medical Concepts (TMCI) has 7 years of Net Income towards Common Stockholders data on file, last reported at -$18.2 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 13.61% year-over-year to -$18.2 million; the trailing twelve-month figure through Mar 2026 stood at -$58.9 million (down 10.33% YoY), and the FY2025 full-year result was -$56.7 million, down 1.12% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$18.2 million, down from -$6.7 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at -$619000.0 in Q4 2024 and bottomed at -$21.3 million in Q2 2024.
• The 5-year median for Net Income towards Common Stockholders is -$15.4 million (2024), against an average of -$13.2 million.
• The widest annual swing landed in 2024, when Net Income towards Common Stockholders jumped 90.29%; it then slumped 989.66% in 2025.
• A 5-year view of Net Income towards Common Stockholders shows it stood at -$4.4 million in 2022, then sank by 44.54% to -$6.4 million in 2023, then surged by 90.29% to -$619000.0 in 2024, then plunged by 989.66% to -$6.7 million in 2025, then plunged by 170.36% to -$18.2 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$18.2 million (Q1 2026), -$6.7 million (Q4 2025), and -$16.4 million (Q3 2025), per Business Quant data.

Peer Comparison